ClinicalTrials.gg
WithdrawnNCT06983964Updated Oct 15, 2026

Safety and Efficacy of CD19 CAR-T Therapy for Recurrent/Refractory Autoimmune Diseases

An interventional study of CD19 CART in Autoimmune Disease, sponsored by Beijing Boren Hospital. Withdrawn at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Beijing Boren Hospital · Not applicable, Interventional, and Treatment

How we know

Why this study was withdrawn
No participants.
Updated Oct 15, 2026Now WithdrawnPrimary completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 125 studies in Autoimmune Diseases with a site in China — 72 open to participants now, 78 under way, 7 of them phase 3. Autoimmune Diseases · China.

Enrollment
107th of 113
0 · median 30
Started
2025
with 31 others
No phase
21 of 125
14 open now
Registered
81st of 125
by date
Lead sponsor
5 of 125
Beijing Boren Hospital

Among the 125 studies in Autoimmune Diseases with a site in China, this one is the 107th largest by enrollment of the 113 interventional ones that give a count, is one of 32 that started in 2025, is one of 21 with no phase, and was the 81st registered.

Autoimmune Diseases

804 studies on the registry are indexed under Autoimmune Diseases; 273 are open to participants now.

Browse Autoimmune Diseases studies →

Open to participants now

72 of the 125 studies in Autoimmune Diseases with a site in China are open now. Recruiting first, the newest first:

67 more — sign in →

All 72 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 195 Autoimmune Diseases studies recruiting now, 90 (46%) set no upper age limit and 79 (41%) stop at 75 or younger; 55 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 125 studies in Autoimmune Diseases with a site in China, or all of them as a file.
02

Study summary

This study is a single center, open label exploratory clinical trial aimed at evaluating the safety and efficacy of universal CD19 CAR-T therapy in subjects with autoimmune diseases.

The study will adopt the traditional dose escalation model "3+3" design, setting up three dose groups with a starting dose of 0.5 × 106 CAR+T cells/kg for incremental DLT observation. Safety and efficacy follow-up will be conducted for 24 months after cell infusion to observe the safety of the universal CD19 CAR-T and conduct preliminary efficacy evaluation.

03

Conditions studied

  • Autoimmune Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must meet all of the following inclusion criteria in order to be included in this study;
  • Age range of 18 to 65 years old (including 18 and 65 years old), gender is not limited;
  • Special criteria for different indications:
  • Subjects with moderate to severe SLE must meet the following criteria:
  • According to the 2019 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria, the diagnosis is SLE;
  • Positive for anti nuclear antibody (ANA) (titer ≥ 1:80), and/or positive for anti dsDNA antibody, and/or positive for anti Sm antibody during screening;
  • The definition of moderate to severe activity is: SLEDAI-2000 score ≥ 8 during screening; If there is a low complement and/or anti dsDNA antibody score, the clinical symptom score for SLEDAI-2000 (excluding low complement and/or anti dsDNA antibodies) must be ≥ 6 points;
  • At least 6 months of stable standard treatment have been used in the SLE history prior to screening, and the condition remains active for at least 2 months prior to screening. The standard treatment plan refers to the stable use of any of the following drugs (used alone or in combination): (≤ 20mg/day prednisone or equivalent), antimalarials (hydroxychloroquine ≤ 400mg/day, chloroquine ≤ 500mg/day), nonsteroidal anti-inflammatory drugs (NSAIDs), biologics (rituximab, belimumab, tacept), and other or immunomodulators, including mycophenolate mofetil (≤ 2g/day), azathioprine (≤ 2mg/kg/day), methotrexate (≤ 20mg/week), etc;
  • Recurrent/refractory dcSSc subjects must meet the following criteria:
  • According to the 2013 EULAR/ACR classification criteria for systemic sclerosis (SSc), the diagnosis is SSc; 2) According to the definition criteria of LeRoy et al. in 1988, it meets the diffuse skin type presentation, which refers to extensive skin fibrosis and involvement of the skin near the elbow and/or knee;
  • When screening, interstitial lung disease (ILD) should be included, and 45% of the predicted values should be ≤ forced vital capacity (FVC) ≤ 70% of the predicted values, or 40% of the predicted values should be ≤ diffusion capacity of carbon monoxide (DLCO) ≤ 70% of the predicted values;
  • Relapse/refractory is defined as: recurrence after previous ineffective conventional treatment or disease remission. Conventional treatment refers to the use of glucocorticoids, cyclophosphamide, and at least one immunosuppressive/regulatory drug for at least 6 months. Immunosuppressive/regulatory drugs include azathioprine, mycophenolate mofetil, methotrexate, leflunomide, tacrolimus, cyclosporine, rituximab, belimumab, tacrolizumab, etc;
  • Activity is defined as having at least one of the following:

There is evidence of skin progression during screening, that is, an increase of ≥ 10% in mRSS scores within the past 6 months;

During screening, there is evidence of any of the following ILD activities:

Newly diagnosed ILD within the past 6 months; Previous ILD subjects had a 10% decrease in FVC or a 5% decrease in FVC accompanied by a 15% decrease in DLCO within the past 6 months.

  • Recurrent/refractory AAV subjects must meet the following criteria:
  • According to the definition of the 2012 Chapel Hill Consensus Conference (CHCC), clinical diagnosis is granulomatous vasculitis (GPA) and microscopic polyangitis (MPA);
  • In Birmingham Vasculitis Activity Score (BVAS) version 3, at least one primary item or at least three other items;
  • During screening, antibodies against PR3-ANCA or MPO-ANCA were positive;
  • The definition of recurrence/refractory is:

Recurrent AAV subjects: those who have received initial efficacy (BVAS score 0 and glucocorticoid dose ≤ 7.5mg/d prednisone or other equivalent glucocorticoid drugs) after at least 3 months of combined glucocorticoid and immunosuppressive therapy (cyclophosphamide, rituximab, azathioprine, methotrexate, mycophenolate mofetil, etc.), and have experienced at least 1 disease recurrence (recurrence defined as the appearance of at least one important item in BVAS assessment, or at least 3 other items, or 1-2 new items in two consecutive assessments), and have experienced disease recurrence within 12 weeks before screening; Difficult to treat AAV subjects: Despite at least 3 months of previous treatment with corticosteroids combined with immunosuppressants (cyclophosphamide, rituximab, azathioprine, methotrexate, mycophenolate mofetil, etc.), no therapeutic effect has been achieved (BVAS score 0 and glucocorticoid dose ≤ 7.5mg/d prednisone or other equivalent glucocorticoid drugs);

  • Recurrent/refractory IIM subjects must meet the following criteria:
  • According to the 2017 EULAR/ACR IIM classification criteria, the probability of being diagnosed with IIM is ≥ 55%, and based on factors such as age of first onset, skin and muscle strength, laboratory tests, and muscle characteristics, it is classified as dermatomyositis (DM), polymyositis (PM), or immune-mediated necrotizing myopathy (IMNM):
  • Disease activity/severity meets the following criteria:

Manual muscle strength check-8 (MMT-8) score ≤ 141 (total score of 150):

Meet at least 2 of the anomalies in other CSMs:

The overall disease activity evaluated by the patient [based on Visual Analog Scale (VAS)] score is ≥ 2 points (range 0-10 points); The overall disease activity VAS score evaluated by physicians is ≥ 2 points (range 0-10 points); The overall extramuscular disease activity VAS score evaluated by the physician is ≥ 2 points (range 0-10 points); The Health Assessment Questionnaire Disability Index (HAQ-DI) score evaluated by physicians is ≥ 0.25 (range 0-3 points).

At least one muscle enzyme level is greater than 1.5 times the (ULN).

  • Recurrent/refractory SS subjects must meet the following criteria:
  • According to the 2016 EULAR/ACR SS classification criteria, the diagnosis is SS;
  • Positive for anti Ro/SSA antibodies during screening;
  • Dynamic saliva total flow rate ≥ 0.05 mL/min or static saliva total flow rate ≥ 0.01 mL/min during screening;
  • Activity is defined as a Dry Syndrome Disease Activity Index (ESSDAI) score of ≥ 5 across 8 sub items;
  • For diseases that are intolerant to or have insufficient efficacy in the treatment of glucocorticoids and at least one other immunosuppressant or modulator in the past, it is required to be treated with glucocorticoids and at least two immunosuppressants (azathioprine, methotrexate, mycophenolate mofetil, etc.) at known effective doses for at least 3 months;
  • Having good organ function:
  • Blood routine: (ANC) ≥ 0.5 × 109/L, count (PLT) ≥ 20 × 109/L, ≥ 60 g/L;
  • Coagulation function: (INR) ≤ 1.5 times ULN, and activated partial thromboplastin time (APTT) ≤ 1.5 times ULN;
  • Liver function: serum (AST), alanine aminotransferase (ALT) ≤ 3 times the upper limit of normal (ULN), total ≤ 1.5 times ULN;
  • Renal function: serum creatinine ≤ 1.5 × ULN or rate (Cockcroft Gault formula) ≥ 30 mL/min;
  • Cardiac function: grade I or II, with an echocardiogram (ECHO) (LVEF) ≥ 50% and no pericardial effusion; There were no abnormal findings in the 12 lead (ECG);
  • Pulmonary function: Under indoor ventilation conditions, the oxygen saturation in non oxygenated state is ≥ 92%; No clinically significant pleural effusion;
  • Expected survival period greater than 6 months;
  • Subjects with reproductive partners agree to use effective measures throughout the entire treatment period and for 24 months after treatment, and are not allowed to donate eggs/sperm for assisted reproduction during this period; Female subjects of childbearing age (those who have undergone sterilization surgery or have been menopausal for ≥ 12 months are not considered fertile) with negative urine pregnancy or blood pregnancy tests during the screening period; Voluntarily participate in this experiment and sign the form.

Exclusion criteria

Exclusion Criteria:

  • Subjects who meet any of the following criteria are not eligible for inclusion in this study:
  • Patients with previous or concurrent active malignant tumors, including tumor associated polymyositis/dermatomyositis. Cervical carcinoma in situ that has been cured or has not recurred for at least 2 years, non-invasive basal cell or squamous cell skin cancer, locally treated prostate cancer, and ductal carcinoma in situ after radical surgery are excluded;
  • Within the past 3 months, severe pulmonary diseases such as moderate to severe pulmonary arterial hypertension (average pulmonary arterial pressure detected by echocardiography>60 mmHg) require oxygen mask therapy or non-invasive or invasive ventilator assisted breathing during screening; During screening, IgA, IgG, and IgM levels were below the lower limit of normal (LLN);
  • Patients who have used any of the following medications or treatments within the specified time:
  • Individuals who have used B-cell depletion therapy within the previous month and have not failed treatment as assessed by clinical physicians, including those targeting CD20, CD22, CD52, CD38, BCMA monoclonal antibodies, or bispecific antibodies;
  • Screening for excessive use of human intravenous immunoglobulin within the previous month;
  • Use therapeutic doses of (prednisone ≥ 20mg/day or equivalent doses of other corticosteroids) within 24 hours prior to Qinglin pretreatment;
  • Received corticosteroid shock therapy within 2 weeks (defined as a dose ≥ 500mg/d of prednisone or equivalent dose of other corticosteroids);
  • Received tacrolizumab within 2 weeks prior to screening, or received belimumab within 3 weeks;
  • Patients with a history of severe central nervous system diseases or related symptoms (excluding simple trigeminal nerve disease) within the past 6 months, including but not limited to: lupus encephalopathy, cerebrovascular disease, encephalitis, brain injury, aneurysm, cerebellar disease, organic brain syndrome, Parkinson's disease and other central nervous system diseases, as well as epilepsy, seizures, aphasia, dementia and other symptoms;
  • Individuals who have experienced lupus crisis within the previous 3 months, such as active central nervous system lupus, severe hemolytic anemia, severe thrombocytopenic purpura, severe neutropenia, severe myocardial injury, severe lupus pneumonia or pulmonary hemorrhage, severe lupus hepatitis, severe vasculitis, etc;
  • Concurrent severe kidney disease: severe lupus nephritis (defined as urinary protein>4g/24 hours or serum creatinine>1.5 × or rate (Cockcroft Gault formula)\<30 mL/min) within the first 8 weeks of screening, Or active nephritis that requires treatment with drugs prohibited by the protocol, or requires treatment with prednisone greater than 500mg/day or equivalent corticosteroids for ≥ 14 days;
  • Individuals who have severe allergies to any components of the Qinglin pre-treatment drug and the universal CD19 CAR-T used in this study;
  • surface antigen (HBsAg) positive and peripheral blood HBV DNA positive; Individuals with positive virus (HCV) antibodies and positive HCV RNA; Positive for Treponema pallidum antibody; antibody positive individuals;
  • There are uncontrolled fungi, bacteria, viruses, or other infections that researchers have assessed as unsuitable for participation in the study;
  • History of major organ transplantation (such as heart and lung);
  • During screening, there is active tuberculosis or latent tuberculosis (referring to whether the tuberculin skin test or interferon test is positive, and there are no clinical symptoms or imaging evidence);
  • If any of the following cardiovascular diseases (including but not limited to) have occurred within the 6 months prior to screening:
  • Congestive heart failure, myocardial infarction, unstable angina, coronary angioplasty, stent implantation, coronary artery/peripheral artery bypass grafting;
  • Serious arrhythmias that require treatment (such as persistent ventricular tachycardia, ventricular fibrillation, apical torsion ventricular tachycardia, etc.); Congenital long syndrome, left anterior half block (double bundle block), allowing asymptomatic right bundle branch block to be included in the study;
  • Uncontrolled hypertension (systolic blood pressure greater than 160 mmHg and/or diastolic blood pressure greater than 100 mmHg), history of hypertensive crisis or hypertensive encephalopathy;
  • In addition to the target indication, patients with a history of other diseases (including but not limited to eosinophilic granulomatous polyangitis, cryoglobulinemia vasculitis, inclusion body myositis, anti glomerular basement membrane disease, Behcet's disease or Takayasu arteritis, etc.) who require systematic treatment;
  • Individuals with a family history of non IIM such as drug-induced myopathy or human immunodeficiency virus related myopathy;
  • Pregnant or lactating women;
  • Those who have received a within 6 weeks before the pre-treatment of Qinglin;
  • Participants who have participated in other interventional clinical studies, received active drug treatment, or intended to participate in another clinical trial or receive treatment for autoimmune diseases outside of the protocol within 3 months prior to signing the form during the entire study period;
  • Mental illness patients with depression or suicidal tendencies; The researchers believe that there are other factors that are not suitable for inclusion or affect the participation or completion of the study by the subjects.
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Universal CD19 CAR-T

    Genetic: CD19 CART

Interventions

  • GeneticCD19 CART

    Dose group dosage unit (CAR+T cells/kg) Acceptable dose range Expected sample size (± 30%, CAR+T cells/kg) 1. 0.5 × 106 0.4 × 106\~0.6 × 106 3-6 cases 2. 1.0 × 106 0.7 × 106\~1.3 × 106 3-6 cases 3. 2.0 × 106 1.4 × 106\~2.6 × 106 3-6 cases Dose escalation rule The enrollment starts from dose group 1, and if no DLT occurs in the 3 subjects included, they will be transferred to the next dose group. If one of the three subjects in a certain dose group develops DLT, three additional subjects will be added to the group for cell infusion at the same dose. If there is ≥ 1 case of DLT in the 3 additional cases, it will be reduced to the previous dose group. If there are only 3 subjects in the previous dose group at this time, an additional 3 subjects need to be added for the trial; If there are already 6 subjects in the previous dose group, the trial ends and this dose is the maximum tolerated dose (MTD).

06

What researchers measure

Primary outcomes

  1. Dose limiting toxicity (DLT)

    Time frame: 0~28 day after treatment

07

Study locations

1 site
  • Beijing Gobroad Brond Hospital
    Beijing, Beijing Municipality 100070, China
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Feb 2025 to primary completion in Apr 2026, 14 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 15, 2026: primary completion Feb 2027 → Apr 2026 and completion Sep 2027 → Apr 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 18, 2025
First posted
May 21, 2025
StartActual
Feb 20, 2025
Primary completionActual
Apr 30, 2026was Feb 2027
CompletionActual
Apr 30, 2026was Sep 2027
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Withdrawn No participants.
changed Oct 15, 2026
Sites
1 site added, 1 site removed
Show site
  • Beijing Gobroad Brond Hospital · Beijing, China
Show 1 removed
  • Beijing Gobroad Brond Hospital · Beijing, China
Oct 15, 2026
Primary completion
Feb 20, 2027→Apr 30, 2026 (actual)
Oct 15, 2026
Study completion
Sep 30, 2027→Apr 30, 2026 (actual)
Oct 15, 2026
Enrollment
12 (estimated)→0 (actual)
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Recruiting→Withdrawn
    Why stopped No participants.
    1 site added, 1 site removed
    Show site
    • Beijing Gobroad Brond Hospital · Beijing, China
    Show 1 removed
    • Beijing Gobroad Brond Hospital · Beijing, China
    Primary completion Feb 20, 2027→Apr 30, 2026 (now actual)
    Study completion Sep 30, 2027→Apr 30, 2026 (now actual)
    Enrollment 12 (estimated)→0 (actual)
    + 3 other changes: index terms, verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06983964
Lead sponsor
Beijing Boren Hospital
Responsible party
Sponsor
First posted
May 21, 2025
Start date
Feb 20, 2025
Primary completion
Apr 30, 2026
Completion
Apr 30, 2026
Last update
Oct 15, 2026

Study contacts

yajing zhang, MD/PhD
principal investigator · Beijing Gaobo Boren Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion